Relmada Therapeutics (RLMD) Shares Outstanding (Weighted Average) (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Shares Outstanding (Weighted Average) data on file, last reported at $86.6 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 184.77% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (up 184.77% YoY) and the FY2025 annual result came in at $4.2 million, down 86.04% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $86.6 million in Q1 2026 per RLMD's latest filing, from $4.2 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $86.6 million in Q1 2026 and bottomed at $5417.0 in Q3 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $30.1 million (2023), against an average of $28.7 million.
• Peak annual rise in Shares Outstanding (Weighted Average) reached 718304.01% in 2022, while the deepest fall reached 99.97% in 2022.
• Tracing RLMD's Shares Outstanding (Weighted Average) over 5 years: stood at $29.6 million in 2022, then climbed by 1.59% to $30.1 million in 2023, then gained by 0.21% to $30.2 million in 2024, then slumped by 86.04% to $4.2 million in 2025, then surged by 1956.68% to $86.6 million in 2026.
• Per Business Quant, the three latest RLMD Shares Outstanding (Weighted Average) figures stand at $86.6 million (Q1 2026), $4.2 million (Q4 2025), and $33.2 million (Q3 2025).

Peer Comparison